Shenghua
Gu
abc,
Bei
Cao
ad,
Runbin
Sun
a,
Yueqing
Tang
b,
Janice L.
Paletta
c,
Xiao-Lei
Wu
*b,
Linsheng
Liu
a,
Weibin
Zha
a,
Chunyan
Zhao
a,
Yan
Li
b,
Jason M.
Ridlon
e,
Phillip B.
Hylemon
e,
Huiping
Zhou
e,
Jiye
Aa
*a and
Guangji
Wang
a
aState Key Laboratory of Natural Medicines, Key Laboratory of Drug Metabolism and Pharmacokinetics, Jiangsu Key laboratory of drug design and optimization, China Pharmaceutical University, Nanjing 210009, China. E-mail: jiyea@cpu.edu.cn
bCollege of Engineering, Peking University, Beijing 100871, China. E-mail: xiaolei_wu@pku.edu.cn
cCenter for Drug Safety Evaluation and Research, Shanghai University of Traditional Chinese Medicine, China
dNanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, China
eDepartment of Microbiology & Immunology, Virginia Commonwealth University, Richmond, Virginia 23298, USA
First published on 23rd December 2014
Correction for ‘A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine’ by Shenghua Gu et al., Mol. BioSyst., 2015, DOI: 10.1039/c4mb00500g.
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2015 |